Evidence map›Paper›PMID 29311243›Full record

ArticleInfection and immunity2018

The eIF2α Kinase Heme-Regulated Inhibitor Protects the Host from Infection by Regulating Intracellular Pathogen Trafficking.

Wael Bahnan, Justin C Boucher, Petoria Gayle, Niraj Shrestha, Mark Rosen, Bertal Aktas, Becky Adkins, Arba Ager, Wasif N Khan, Kurt Schesser

Abstract read
In one paragraph

Article in Infection and immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Hemopexin reverses activation of lung eIF2α and decreases mitochondrial injury in chlorine-exposed mice.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  2. Article
  3. Signaling plasticity in the integrated stress response.Frontiers in cell and developmental biology · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wael BahnanDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Justin C BoucherDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Petoria GayleDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Niraj ShresthaDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Mark RosenJanssen Research & Development, San Diego, California, USA.
Bertal AktasHematology Laboratory for Translational Research, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Becky AdkinsDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Arba AgerDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Wasif N KhanDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA wnkhan@med.miami.edu kschesser@med.miami.edu.
Kurt SchesserDepartment of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA wnkhan@med.miami.edu kschesser@med.miami.edu.ORCID https://orcid.org/0000-0003-0515-3850

Funding

Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 DiabetesR01DK084246 · NIDDK · WASHINGTON UNIVERSITY · PI KENDALL, PEGGY L · 2011 to 2019
$3.2M
Allosteric Costimulatory BlockadeR01AI101041 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BUCHWALD, PETER · 2012 to 2016
$1.9M
Targeting Endoplasmic Reticulum Stress Response for Cancer TherapyR01CA152312 · NCI · HARVARD MEDICAL SCHOOL · PI AKTAS, BERTAL H. · 2011 to 2015
$1.8M
Cellular analysis of the Yersinia protein kinase AR01AI053459 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SCHESSER, KURT R · 2004 to 2008
$1.3M
NCI NIH HHS R01 CA152312NIAID NIH HHS R01 AI053459NIAID NIH HHS R01 AI101041NIDDK NIH HHS R01 DK084246
6 · The paper itself

Abstract

The host employs both cell-autonomous and system-level responses to limit pathogen replication in the initial stages of infection. Previously, we reported that the eukaryotic initiation factor 2α (eIF2α) kinases heme-regulated inhibitor (HRI) and protein kinase R (PKR) control distinct cellular and immune-related activities in response to diverse bacterial pathogens. Specifically for

Indexed as

AnimalsFemaleHumansInterleukin-6Listeria monocytogenesListeriosisMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutPhosphorylationProtein Serine-Threonine KinaseseIF2alpha kinase, mouseInterleukin-6Protein Serine-Threonine KinaseseIF2α kinaseheme-regulated inhibitorHRIListeria monocytogenesmacrophagesmicrobial pathogenesisstress response

Identifiers

PMID29311243
PMCPMC5820965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.